Navigation Links
Teva Pharmaceuticals Donates to the National Multiple Sclerosis Society in recognition of Jack Osbourne as He Competes on "Dancing with the Stars"
Date:9/17/2013

FRAZER, Pa., Sept. 17, 2013 /PRNewswire/ -- As part of Teva Pharmaceuticals' ongoing commitment to improving the lives of people living with multiple sclerosis (MS), the company will make a $100,000 donation to the National Multiple Sclerosis Society in recognition of MS advocate, television host and film and TV producer Jack Osbourne, who has relapsing-remitting multiple sclerosis (RRMS) and is currently competing on "Dancing with the Stars." RRMS is the most common form of MS, in which a person experiences episodes of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.

"Teva is happy to continue our long-standing partnership with the National MS Society.  Our goals align - the ongoing support of, and commitment to the MS community - and for Teva, that commitment dates back more than twenty years," said Mike Derkacz, vice president and general manager, Teva CNS.  "We are proud to make this donation to the National MS Society and recognize the great work they do for people who live with MS and RRMS, like Jack Osbourne. We wish Jack well as he competes on 'Dancing with the Stars.'"

"On behalf of the National MS Society and all the people with MS that we serve, we want to thank Teva and Jack Osbourne for building awareness about MS," says Cyndi Zagieboylo, president and CEO of the National MS Society. "This donation will foster the national conversation to build greater understanding of MS, honor the spirit of all those moving their lives forward despite the challenges of MS, and support research that will one day end MS forever."

Teva is partnering with Jack Osbourne on an MS awareness campaign entitled, "You Don't Know Jack about MS," set to launch later this fall. 

About Jack Osbourne
The youngest child of heavy metal icon Ozzy Osbourne and "The Talk" host Sharon Osbourne, Jack Osbourne is a television personality and producer of film and television projects through his production company Schweet Entertainment. Jack and his wife, Lisa Osbourne, have a daughter, Pearl, who was born in 2012 just two weeks before he was diagnosed with relapsing-remitting multiple sclerosis (RRMS), the most common form of MS. Since his diagnosis, Jack has worked as a passionate multiple sclerosis (MS) advocate, speaking out about the need for MS research and greater awareness. 

About Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. In the U.S. today, there are approximately 400,000 people living with MS. In relapsing-remitting MS, the most common form of the disease, a person experiences attacks (also called relapses or exacerbations) of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Denise Bradley (215) 591-8974
Nancy Leone (215) 284-0213


'/>"/>
SOURCE Teva Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
2. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
3. Frost & Sullivan Lauds Adcock Ingrams Capability to Innovatively Cater to the Dynamic Needs of Emerging Pharmaceuticals Markets
4. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
5. Access Pharmaceuticals Awarded Second European Patent for MuGard
6. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
7. Caldera Pharmaceuticals Announces Closing of Financing
8. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
9. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
10. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
11. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s ... of his paramedic experiences. Schanssema describes the tragedies he saw, as well as his ... them. , Schanssema, initially unsure of the career path he wanted to take, found ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning sunscreen ... Fondo of Marin. For the second year in a row, cyclists will stay ... “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
Breaking Medicine News(10 mins):